stockrowViking Therapeutics, Inc.
VKTX Healthcare Biotechnology
- EPS
- −91.6%
- Free cash flow
- −47.0%
Quarter to September 2026, against a year earlier
Follow VKTX
Alert me
Viking Therapeutics, Inc. (VKTX) Return on assets
Viking Therapeutics, Inc.'s return on assets over the twelve months to 30 September 2026 was −73.1%, down 28.8 percentage points from fiscal 2025 (−44.3%). Over the past ten years it has ranged from −253.3% (fiscal 2015) to −8.79% (fiscal 2019); the current reading is higher than 36% of that period. That is below the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −44.3% | (27.07) |
| FY2024 | −17.2% | 14.77 |
| FY2023 | −32.0% | 4.33 |
| FY2022 | −36.3% | (12.78) |
| FY2021 | −23.5% | (8.93) |
| FY2020 | −14.6% | (5.82) |
| FY2019 | −8.79% | 4.81 |
| FY2018 | −13.6% | 98.67 |
| FY2017 | −112.3% | (13.98) |
| FY2016 | −98.3% | 154.97 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 23.2% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| ELVN Enliven Therapeutics, Inc. compare | −15.0% |
| IRON Disc Medicine, Inc. compare | −35.1% |
| XENE Xenon Pharmaceuticals Inc. compare | −41.5% |
| CELC Celcuity, Inc. compare | −44.8% |
| DYN Dyne Therapeutics, Inc. compare | −60.3% |
| VKTX Viking Therapeutics, Inc. | −73.1% |
| TARS Tarsus Pharmaceuticals, Inc. compare | −135.0% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)